Micromedic – a Unique Cluster of Cancer Diagnostic Solutions     News
  Micromedic Technologies Ltd. specializes in the development and commercialization of innovative in vitro cancer diagnostic products and solutions. Our portfolio includes state-of-the-art technologies involving gene expression, biomarker and histochemical assays for early cancer detection and personalized medicine.
Micromedic offers proprietary diagnostic solutions for multiple cancer diagnostic applications, providing practical answers to real unmet needs.

Micromedic is a public company traded on the Tel Aviv Stock Exchange (TASE: MCTC).

 
  2-2-2015
Micromedic Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence

1-7-2014
Micromedic Reports Successful Interim Results from Bladder Cancer Clinical Study

27-5-2014
Micromedic identifies new genetic markers to predict risk of developing BRONJ

3-2-2014
Micromedic reports success in clinical pilot of its Cervical Cancer diagnostic product in a central hospital in Beijing

8-7-2013
Zetiq has signed a memorandum of understanding for collaboration in India

25-12-2012
Successful interim results in a trial of a test for recurrence of bladder cancer cells in urine specimens

3-10-2012
Zetiq receives patent approval in Japan for its cell staining technology

20-11-2012
Marketing approval for Zetiq's CellDetect in China

15-4-2012
BioLight will invest 4 million NIS for additional 5% of Micromedic

27-3-2012
Micromedic signed an investment agreement with BioMarCare Technologies Inc.

© Micromedic Technologies Ltd. site mapcontact
 
Site by Site2goal | Design Studio Michal Lehavi